Abstract

Many drugs have been introduced recently which are only minor variants of existing compounds and have no demonstrable advantages (‘me-too’ drugs). Examples include many benzodiazepines and β-adrenoceptor blocking agents. Sensing that these compounds may be marketed for commercial rather than for medical reasons, some doctors wonder whether the Licensing Authority has any control of the situation, and if so whether it is exercised.